Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neuraxis, Inc. Common Stock (NY:NRXS)

3.990 +1.720 (+75.77%)
Official Closing Price Updated: 8:00 PM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neuraxis, Inc. Common Stock

Top movers in Tuesday's after hours session
Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
Gold Gains Over 1%; Amer Sports Posts Upbeat Earnings
Via Benzinga
Nasdaq Falls 100 Points; Home Depot Sales Top Views
Via Benzinga
Earnings Scheduled For May 12, 2025
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
NRXS Stock Earnings: Neuraxis Reported Results for Q2 2024
Neuraxis just reported results for the second quarter of 2024. 
Via InvestorPlace
NRXS Stock Earnings: Neuraxis Reported Results for Q1 2024
Neuraxis just reported results for the first quarter of 2024. 
Via InvestorPlace
NRXS Stock Earnings: Neuraxis Misses Revenue for Q4 2023
NRXS stock results show that Neuraxis missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
SoftBank-Owned Arm, Instacart File To Go Public
Via Talk Markets
Earnings Scheduled For March 20, 2025
Via Benzinga
Earnings Scheduled For April 9, 2024
Companies Reporting Before The Bell • Tilray Brands (NASDAQ:TLRY) is projected to report quarterly loss at $0.05 per share on revenue of $198.62 million. 
Via Benzinga
With Only 1.21 Million In The Trading Float, NeurAxis Stock Volatility Exposes An Opportunity, Not A Deterrent ($NRXS)
Via AB Newswire
Exposures Product Safety
Why CS Disco Are Trading Lower By 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Tenon Medical, Inc. (NASDAQ: TNON) shares climbed 63.5% to $0.2351 after the company announced it has withdrawn its proposed public offering of shares of its common stock. 
Via Benzinga
EXCLUSIVE: NeurAxis' Nerve Field Stimulation Tech Shows Improved Quality of Life of Adolescents Patients With Irritable Bowel Syndrome
NeurAxis Inc (NYSE: NRXS) announced the publication of a Prospective study evaluating the efficacy of IB-Stim in children featured in the September 2023 Frontiers in Pain Research. 
Via Benzinga
CEO Spotlight: NeurAxis CEO Explains His Better Way Of Treating Pediatric IBS And FAP ($NRXS)
Via AB Newswire
NeurAxis Looks To Revolutionize The Treatment Of Adolescent Stomach Issues
NeurAxis, Inc. (NYSEAMERICAN: NRXS) looks to revolutionize how pediatric irritable bowel syndrome (IBS) and functional abdominal pain (FAP) are treated.   
Via Benzinga
EXCLUSIVE: Small MedTech Firm NeurAxis Targets $2B Market With Post-Concussion Therapy In Kids
NeurAxis Inc (NYSE: NRXS) highlighted A Prospective Study on the Effect of Auricular Percutaneous Electrical Nerve Field Stimulation (PENFS) in Patients with Post-Concussion Syndrome (PCS), a... 
Via Benzinga
NeurAxis Announces Positive University of Michigan IB-Stim™ Cost Effectiveness Study at ANMS 2023
From NeurAxis, Inc.
Via GlobeNewswire
Alcoholic Beverage Marketing Company LQR Debuts On Nasdaq
LQR House, which provides digital marketing and branding services to the alcohol industry, went public on Thursday, raising $5 million million in its IPO. Meanwhile NeurAxis, raised $7 million in its... 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Goldman Small Cap Research Publishes New Research Report on NeurAxis, Inc.
Via ACCESSWIRE
NeurAxis Highlights Current Commercial Insurance Coverage with BCBS Massachusetts, BCBS South Carolina, BCBS Nebraska, and Quartz Wisconsin
From NeurAxis, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.